Glycine substitutes and precursors for treating a psychosis

• US 6,355,681 B2
• Filed: 05/27/1999
• Issued: 03/12/2002
• Est. Priority Date: 12/07/1995
• Status: Expired due to Fees

• Current Assignee: GlyTech, Inc.
• Original Assignee: GlyTech, Inc.
• Inventors: Javitt, Daniel C.
• Primary Examiner(s): Ponnaluri, Padmashri
• Application Number:
  US09/320,446
• Publication Number:
  US 20020013364A1
• Time in Patent Office: 1,020 Days
• Field of Search: 514/531, 514/561, 514/551, 514/578, 514/563, 514/762, 514/663, 514/554, 514/474, 514/458, 514/49, 514/45, 514/42
• US Class Current: 514/561
• CPC Class Codes: A61K 31/16 Amides, e.g. hydroxamic acids
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Process for treating psychosis such as schizophrenia using a glycine substitute or a precursor thereof to potentiate NMDA receptormediated neurotransmission.

Claims

1. A process for treating a human patient having a psychosis which comprises administering to said patient a full agonist substitute for glycine at the glycine-binding site of the NMDA receptor complex in an amount sufficient to potentiate NMDA receptor mediated neurotransmission.

2. The process of claim 1 wherein the psychosis is schizophrenia.

3. A process for treating a human patient having a psychosis which comprises administering to said patient threonine in an amount sufficient to potentiate NMDA receptor mediated neurotransmission.

4. The process of claim 3 wherein the psychosis is schizophrenia.